In brief: SciGen, Cryptome, Circadian, ChemGenex, Synchrotron
Thursday, 04 August, 2005
SciGen (ASX:SIE) executive vice-chairman and founder Saul Mashaal has been reappointed as CEO, a position he held until September 2001 when executive management of the company was transferred to Australia. He will continue to be responsible for the company's business development, in and out-licensing, R&D and manufacturing.
Cryptome Pharmaceuticals (ASX:CRP) has signed up UK-based business development consultant, Dr Deborah Allen, to implement the company's revenue-generating strategy.
Circadian Technologies (ASX:CIR) has appointed Don Clarke and Dominique Fisher as non-executive directors. Don Clarke is a partner with Minter Ellison and Dominique Fisher is principal and executive director of EC Strategies, which advises local and overseas companies on electronic commerce strategies and major commercial transactions.
ChemGenex Pharmaceuticals (ASX:CXS) has accepted an invitation to join the Nasdaq Health Care Index, joining compatriot Psivida.
The Australian Synchrotron has signed a memorandum of understanding on scientific collaboration with the Advanced Photon Source, America's largest and most powerful synchrotron.
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
Perioperative trial offers insights into brain cancer treatment
Victorian brain cancer researchers have used an innovative process to learn how a new drug...
